If Lp(a) particles already count toward ApoB, why measure Lp(a) separately? Because ApoB reflects the overall number of atherogenic particles: those that can contribute to plaque in arteries. It does not tell you how many are Lp(a). A separate Lp(a) test measures the concentration of that particle. A higher result is associated with higher cardiovascular risk.
Apolipoprotein B (ApoB) is the protein used to assess particle number. Lipoprotein(a) is a particular LDL-like particle that contains ApoB plus another protein, apolipoprotein(a). Their overlap does not make the tests interchangeable.
LDL-C, ApoB and Lp(a): three different readings
| Result | What it tells you | What it does not tell you |
|---|---|---|
| LDL-C | The reported LDL cholesterol level includes cholesterol carried by LDL particles and by Lp(a). | The number of plaque-forming particles or your separate Lp(a) level. |
| ApoB | An estimate of atherogenic particle number, including Lp(a) particles. | How much of that total is Lp(a). |
| Lp(a) | The concentration of this specific, largely inherited lipoprotein. | The overall number of atherogenic particles. |
An ApoB result therefore cannot stand in for an Lp(a) measurement. Equally, an Lp(a) result does not replace the rest of your lipid panel. Bring the report to the conversation rather than trying to choose a single “best” number.
What the 2026 U.S. guideline says about testing
The 2026 U.S. multisociety dyslipidemia guideline treats these tests differently: Lp(a) measurement is recommended at least once in all adults, while ApoB measurement is selective.
Lp(a) is mostly genetically determined and generally remains similar over time. “At least once” is not a recommendation to repeat it with every lipid panel.
Clinicians may consider ApoB testing in some adults to clarify cardiovascular risk, including people who already take cholesterol-lowering medication and people who do not.
The useful question is whether the additional result would change your clinician’s interpretation or care planning. Selective testing does not mean everyone needs ApoB added to every panel.
Sources and scope
This article explains the tests for a preventive care conversation. It does not interpret an individual result or recommend treatment.
- Blumenthal RS and colleagues. 2026 Guideline on the Management of Dyslipidemia. Circulation. Sections 3.3, “Measurement of ApoB,” and 3.4, “Measurement of Lp(a).” DOI: 10.1161/CIR.0000000000001423. Read the guideline record on PubMed.
- Koschinsky ML and colleagues. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. Journal of Clinical Lipidology. 2024. DOI: 10.1016/j.jacl.2024.03.001. Supports the clarification that reported LDL-C includes cholesterol carried by Lp(a).
Two questions to take to your preventive care visit
Use the report you have as the starting point. Ask your clinician:
- Have I ever had Lp(a) measured, and is that result available in my record?
- Could an ApoB result change how you interpret my lipid panel or plan my care?
